Anticancer

Ginsenoside Rk2
Catalog No: CFN92818

Ginsenoside Rk1 has anti-tumor, and anti-platelet aggregation activities. Ginsenoside Rk1 can strongly inhibit permeability induced by VEGF, advance glycation end-product, thrombin, or histamine in human retinal endothelial cells, it reduces the vessel leakiness of retina in a diabetic mouse model; this anti-permeability activity of Rk1 is correlated with enhanced stability and positioning of tight junction proteins at the boundary between cells; Rk1 induces phosphorylation of myosin light chain and cortactin, which are critical regulators for the formation of the cortical actin ring structure and endothelial barrier.

3-Deoxysappanchalcone
Catalog No: CFN92833

3-Deoxysappanchalcone is an effective HO-1 inducer at the translational level. 3-Deoxysappanchalcone has anti-inflammatory, and anti-influenza virus activities, the mechanism involved anti-apoptosis and anti-inflammation activities in vitro. It has inhibitory activity on MMP-9 expression and production in TNF-α-treated cells, is mediated by the suppression of AP-1 and NF-κB activation.

Viniferin
Catalog No: CFN92854

α-Viniferin has anti-oxidant and anticancer activities, it strongly inhibits the activities of the two CYPs dose dependently. α-Viniferin suppresses the expression of proinflammatory genes iNOS and COX-2 in the early stage of inflammation by inhibiting the Akt/PI3K-dependent NF-κB activation and inhibits the production of proinflammatory mediators NO and PGE2 in the late stage by stimulating Nrf2-mediated HO-1 signaling pathway in LPS-stimulated BV2 microglial cells. ɛ-Viniferin and vincristine can enhance the anti-tumor effects efficiently by inducing HepG2 cell apoptosis.

Kansuiphorin C
Catalog No: CFN92861

Kansuiphorin C shows cytotoxic activity.

Kansuinine A
Catalog No: CFN92863

Kansuinine A possesses analgesic props, it also shows NGF inducing activity.